Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

Author(s):
Huizinga, T.W.J. (0000-0001-7033-7520); Batalov, A.; Stoilov, R.; Lloyd, E.; Wagner, T.; Saurigny, D.; Souberbielle, B.; Esfandiari, E.
Published
2017
Publication type
Article / Letter to editor
GM-CSFNamilumabPhase 1bRheumatoid arthritis
Date issued
2017-03-09
Language
English
Is part of
Arthritis Research and Therapy
hdl
1887/114629
doi
10.1186/s13075-017-1267-3